Literature DB >> 621280

Prevention of chronic experimental pyelonephritis by suppression of acute suppuration.

M P Glauser, J M Lyons, A I Braude.   

Abstract

In order to evaluate the importance of suppuration, persistent infection, and scar formation in the evolution of Escherichia coli chronic pyelonephritis, we treated rats with different antibiotic regimens at different stages of the disease. The results show that (a) if acute suppurative pyelonephritis is aborted with early antibiotic therapy, chronic pyelonephritis is prevented; (b) chronic pyelonephritis can develop even after eradication of infection if acute suppuration persists beyond 3 days; (c) persistent infection does not lead to chronic pyelonephritis, if the acute suppuration is suppressed; and (d) residual infection, antigen-load, antibody, and(or) cell-dependent autoimmune processes did not play a significant role. We interpret these results as evidence that the pathologic entity recognized as chronic pyelonephritis results from kidney damage, scarring and shrinkage secondary to acute suppuration.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 621280      PMCID: PMC372551          DOI: 10.1172/JCI108951

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Chronic pyelonephritis as a cause of renal failure in dialysis candidates. Analysis of 173 patients.

Authors:  H Schechter; C D Leonard; B H Scribner
Journal:  JAMA       Date:  1971-04-19       Impact factor: 56.272

2.  Autoimmunity in chronic experimental pyelonephritis.

Authors:  T E Miller; J W Smith; J W Lehmann; J P Sanford
Journal:  J Infect Dis       Date:  1970-09       Impact factor: 5.226

3.  Pyelonephritis. VII. Experimental ascending infection with progression of lesions in the absence of bacteria.

Authors:  G M Kalmanson; S C Sommers; L B Guze
Journal:  Arch Pathol       Date:  1965-11

4.  "Active" chronic pyelonephritis without evidence of bacterial infection.

Authors:  M E Angell; A S Relman; S L Robbins
Journal:  N Engl J Med       Date:  1968-06-13       Impact factor: 91.245

5.  An antigenic relationship between kidney and certain Escherichia coli strains.

Authors:  J Holmgren; L A Hanson; S E Holm; B Kauser
Journal:  Int Arch Allergy Appl Immunol       Date:  1971

6.  "Abacterial" and bacterial pyelonephritis. Immunofluorescent localization of bacterial antigen.

Authors:  S Aoki; S Imamura; M Aoki; W R McCabe
Journal:  N Engl J Med       Date:  1969-12-18       Impact factor: 91.245

7.  The cellular kinetics of the immune response in pyelonephritis.

Authors:  T E Miller; D North
Journal:  J Lab Clin Med       Date:  1971-12

8.  Persistence of Bacteria in "Protoplast" Form after Apparent Cure of Pyelonephritis in Rats.

Authors:  L B Guze; G M Kalmanson
Journal:  Science       Date:  1964-03-20       Impact factor: 47.728

9.  Immunization against retrograde pyelonephritis. I. Production of an experimental model of severe ascending Escherichia coli pyelonephritis without bacteremia in rats.

Authors:  S J Brooks; J M Lyons; A I Braude
Journal:  Am J Pathol       Date:  1974-02       Impact factor: 4.307

10.  Retrograde Proteus pyelonephritis in rats. Localization of antigen and antibody in treated sterile pyelonephritic kidneys.

Authors:  R S COTRAN
Journal:  J Exp Med       Date:  1963-05-01       Impact factor: 14.307

View more
  31 in total

1.  Corticosteroids to prevent kidney scarring in children with a febrile urinary tract infection: a randomized trial.

Authors:  Nader Shaikh; Timothy R Shope; Alejandro Hoberman; Gysella B Muniz; Sonika Bhatnagar; Andrew Nowalk; Robert W Hickey; Marian G Michaels; Diana Kearney; Howard E Rockette; Martin Charron; Ruth Lim; Massoud Majd; Eglal Shalaby-Rana; Marcia Kurs-Lasky; Daniel M Cohen; Ellen R Wald; Greg Lockhart; Hans G Pohl; Judith M Martin
Journal:  Pediatr Nephrol       Date:  2020-06-15       Impact factor: 3.714

Review 2.  Reactive oxygen molecules, oxidant injury and renal disease.

Authors:  S P Andreoli
Journal:  Pediatr Nephrol       Date:  1991-11       Impact factor: 3.714

3.  Randomised controlled trial of three day versus 10 day intravenous antibiotics in acute pyelonephritis: effect on renal scarring.

Authors:  D Benador; T J Neuhaus; J P Papazyan; U V Willi; I Engel-Bicik; D Nadal; D Slosman; B Mermillod; E Girardin
Journal:  Arch Dis Child       Date:  2001-03       Impact factor: 3.791

4.  Cellular basis of host defence in pyelonephritis. I. Chronic infection.

Authors:  T E Miller; G Findon; S Cawley
Journal:  Br J Exp Pathol       Date:  1986-02

5.  Cellular basis of host defence in pyelonephritis. II. Acute infection.

Authors:  T E Miller; G Findon; S Cawley; I Clarke
Journal:  Br J Exp Pathol       Date:  1986-04

6.  Experimental pyelonephritis. The effect of T-cell deficiency on the course of hematogenous enterococcal pyelonephritis in the mouse.

Authors:  H Pitchon; R Glassock; G M Kalmanson; L B Guze
Journal:  Am J Pathol       Date:  1984-04       Impact factor: 4.307

7.  Prevention of acute and chronic ascending pyelonephritis in rats by aminoglycoside antibiotics accumulated and persistent in kidneys.

Authors:  J Bille; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

8.  Power Doppler ultrasonography in the diagnosis of acute childhood pyelonephritis.

Authors:  Raphael Halevy; Vladislav Smolkin; Sergey Bykov; Leonid Chervinsky; Waheeb Sakran; Ariel Koren
Journal:  Pediatr Nephrol       Date:  2004-07-06       Impact factor: 3.714

9.  Influence of inflammation on the efficacy of antibiotic treatment of experimental pyelonephritis.

Authors:  P R Meylan; G Braoudakis; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

10.  Extracellular release of reactive oxygen species from human neutrophils upon interaction with Escherichia coli strains causing renal scarring.

Authors:  H Mundi; B Björkstén; C Svanborg; L Ohman; C Dahlgren
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.